NVNO
enVVeno Medical Corporation0.3197
+0.0057+1.82%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
6.46MP/E (TTM)
-Basic EPS (TTM)
-1.08Dividend Yield
0%Recent Filings
8-K
Regains Nasdaq compliance
enVVeno Medical regained Nasdaq compliance on February 4, 2026, after its stock closed at or above $1.00 for 10 straight business days from January 20 to February 2. Cash and investments stood at ~$28 million as of December 31, 2025. Compliance secured. This bolsters its 2026 plans amid forward-looking risks.
8-K
1:35 reverse stock split
8-K
Annual meeting results mixed
enVVeno Medical held its 2025 Annual Meeting on December 11, with 54.70% of shares voting. Stockholders elected Jenusaitis and Berman as Class II directors for three years, ratified CBIZ CPAs as auditors, and authorized a discretionary 1-for-5 to 1-for-35 reverse stock split. They rejected the 2025 Equity Incentive Plan. Existing 2016 plan stays active.
8-K
FDA rejects VenoValve appeal
enVVeno Medical received an unfavorable FDA appeal decision on November 13, 2025, upholding the August 19 not-approvable letter for its VenoValve PMA due to insufficient safety and effectiveness data. CEO Robert Berman pivots resources to next-gen enVVe transcatheter valve, ready for human testing. Cash of $31.5 million funds operations into 2027. Pivotal shift ahead.
COCH
Envoy Medical, Inc.
0.72-0.03
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENOV
Enovis Corporation
26.07-0.47
EW
Edwards Lifesciences Corporatio
85.32+1.94
MDNC
MEDINOTEC INC
5.00+0.00
NAOV
NanoVibronix, Inc.
4.02-0.29
NVCR
NovoCure Limited
12.93-0.04
SNWV
SANUWAVE Health, Inc.
31.46-0.18
VERO
Venus Concept Inc.
2.26+0.59
VYCO
Vycor Medical, Inc.
0.16+0.00